Related Experiment Video
Updated: Jul 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse
Chulapan Engchanil1, Pope Kosalaraksa, Viraphong Lulitanond
1Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. cengchanil@yahoo.com
Insights
Prolonged dual antiretroviral therapy in children can lead to multi-drug resistant HIV mutants. Genotyping identified high rates of nucleoside analog mutations, aiding in future treatment decisions for pediatric HIV.
Area of Science:
- Pediatric infectious diseases
- Virology
- Antiretroviral therapy
Background:
- Prolonged dual antiretroviral therapy (ART) is associated with the emergence of multi-drug resistant human immunodeficiency virus (HIV) mutants.
- Understanding resistance patterns in pediatric populations is crucial for effective HIV management.
Purpose of the Study:
- To determine the prevalence and specific resistance patterns of HIV in children receiving dual nucleoside reverse transcriptase inhibitor (NRTI) therapy.
- To assess the clinical utility of genotypic testing in guiding subsequent treatment regimens.
Main Methods:
- Retrospective review of medical records for HIV-infected children treated with dual NRTIs at Srinagarind Hospital, Thailand.
- HIV genotyping of stored plasma samples to detect specific mutations conferring antiretroviral resistance.
Main Results:
- Sixty percent of 57 children on dual NRTI therapy for a median of 22 months exhibited three or more nucleoside analog mutations (NAMs).
- These NAMs conferred multi-dideoxynucleoside resistance, particularly in children receiving zidovudine and didanosine.
- Genotypic testing revealed significant resistance profiles in this pediatric cohort.
Conclusions:
- Dual NRTI therapy for extended periods in children leads to a high prevalence of NAMs.
- Genotypic resistance testing is a valuable tool for optimizing second-line antiretroviral regimens in pediatric HIV patients.
Background:
Multi-drug resistant HIV mutants have been reported after prolonged dual antiretroviral therapy.
Objective:
To evaluate the prevalence and resistance pattern in HIV-infected children treated with dual NRTIs.
Material And Method:
Records of HIV-infected children treated with dual NRTIs at Srinagarind Hospital, Khon Kaen University, Thailand, were reviewed for baseline data and their consensually-stored plasma were checked for the occurrence of HIV mutants by genotyping.
Results:
Fifty-seven HIV-infected children were treated with dual NRTI regimens (27 males; 30 females). The median age and median CD4+ T-lymphocyte at genotypic testing were 83.5 months and 10.9%, respectively. The median duration of ARV therapy was 22 months. More than half the children (42) were on zidovudine and didanosine. A set of three or more nucleoside analog mutations (NAMs), conferring multi-dideoxynucleoside resistance, was found in 60% of the cases.
Conclusion:
High percentages of NAMs were found in HIV-infected children previously on dual ARV therapy for long periods. Genotypic testing was helpful in designing the second antiretroviral regimen.
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antiviral Nucleoside Inhibitors
Respiratory Syncytial Virus Disease
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Retroviruses

